Dr. Thomas Höger
Chief Executive Officer / CFO
Apogenix: APG101 – A Novel Approach for the Treatment of Cancer
APG101 is a human fusion protein consisting of the extracellular domain of the CD95 receptor fused to the IgG part of an antibody. It binds to the CD95 ligand, thereby blocking the interaction with its cognate receptor. Whereas this interaction triggers apoptosis in many cells, it stimulates invasive growth in cancer cells. Blocking CD95 mediated tumor growth thus represents a novel concept to treating cancer.